Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MK-2870 plus pembrolizumab versus physician's choice after residual triple-negative breast cancer
2023-504962-52-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan, pembrolizumab and capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Invasive Disease-Free Survival. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-504962-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504962-52-00.